Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK govt offers "step change" in support for regenerative medicine

This article was originally published in Scrip

Executive Summary

The UK is at the forefront of regenerative medicine (RM) and has "huge potential" to produce commercially viable therapies and other technologies for a range of diseases. However, for this to happen, the right kind of regulatory and financial support must be provided, a range of scientific and other issues must be overcome, and companies must choose carefully what kind of products or technologies they are prepared to invest in.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts